Manuscript title:

In utero exposure to per – and polyfluoroalkyl substances (PFAS) associates with altered human infant T helper cell development.

Authors:

Darline Castro Meléndez, Department of Immunology, Microbiology and Virology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Nathan Laniewski, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Todd A. Jusko, Department of Public Health Sciences, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Xing Qiu, Departments of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

B. Paige Lawrence, Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Zorimar Rivera-Núñez, Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Environmental and Occupational Health Sciences Institute; Piscataway, New Jersey, USA.

Jessica Brunner, Department of Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Meghan Best, Department of Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Allison Macomber, Department of Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Alena Leger, Department of Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Kurunthachalam Kannan, Department of Environmental Health Sciences, College of Integrated Health Sciences, University at Albany, Albany, NY, USA and Wadsworth Center, New York State Department of Health, Albany, NY, USA

Richard Kermit Miller, Department of Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Emily S. Barrett, Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Environmental and Occupational Health Sciences Institute; Piscataway, New Jersey, USA.

Thomas G. O'Connor, Departments of Psychiatry, Neuroscience, Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Kristin Scheible, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Contact Information corresponding author:

Kristin Scheible, MD

Kristin_Scheible@URMC.Rochester.edu

University of Rochester

601 Elmwood Avenue, Box 651

Rochester, NY 14642

Declaration of competing financial interests (CFI):

The authors declare they have no actual or potential competing financial interests.

Abstract:

Background:

Environmental exposures to chemical toxicants during gestation and infancy can dysregulate multiple developmental processes, causing lifelong effects. There is compelling evidence of PFAS-associated immunotoxicity in adults and children. However, the effect of developmental PFAS exposure on infant T-cell immunity is unreported, and, if present, could be implicated in immune-related health outcomes.

Objectives:

We seek to model longitudinal changes in CD4+ T-cell subpopulations from birth through 12 months and their association with in-utero PFAS exposure and postnatal CD4+ T-cell frequencies and functions.

Methods:

Maternal-infant dyads were recruited as part of the UPSIDE-ECHO cohort during the first trimester between 2015 and 2019 in Rochester, New York; dyads were followed through the infant's first birthday. Maternal PFAS concentrations (PFOS, PFOA, PFNA, and PFHXS) were quantified in serum during the second trimester using high-performance liquid chromatography and tandem mass spectrometry. Infant lymphocyte frequencies were assessed at birth, 6- and 12-months using mass cytometry and high-dimensional clustering methods. Linear mixed-effects models were employed to analyze the relationship between maternal PFAS concentrations and CD4+ T-cell subpopulations (n=200). All models included a PFAS and age interaction and were adjusted for parity, infant sex, and pre-pregnancy body mass index.

Results:

In-utero PFAS exposure correlated with multiple CD4+ T-cell subpopulations in infants. The greatest effect sizes were seen in T-follicular helper (Tfh) and T-helper 2 (Th2) cells at 12 months. A $\log_2$-unit increase in PFOS was associated with lower Tfh [0.17% (95%CI: -0.30, -0.40)] and greater Th2 [0.27% (95%CI: 0.18, 0.35)] cell percentages at 12 months. Similar trends were observed for PFOA, PFNA, and PFHXS.

Discussion:

Maternal PFAS exposures correlate with cell-specific changes in the infant T-cell compartment, including key CD4+ T-cell subpopulations that play central roles in coordinating well-regulated, protective immunity. Future studies into the role of PFAS-associated T-cell distribution and risk of adverse immune-related health outcomes in children are warranted.

Introduction

The immune system development begins in the fetus during gestation and continues after birth. Different immune cell types arise from precursors, which can differentiate and develop in a regulated manner. [1–3] Environmental exposure to harmful agents such as chemical toxicants or deficits in nutrition during gestation and infancy can dysregulate multiple developmental processes influencing health over a lifetime.[4–7] Among these harmful agents, exposure to per- and polyfluoroalkyl substances (PFAS) stands out due to their widespread prevalence and persistence in the environment, [8] and their well-documented associations with several adverse health outcomes across the lifespan, including impaired reproduction, growth, neurodevelopment and liver, kidney and immune dysfunction. [9–14] PFAS are a group of synthetic chemicals characterized by interconnected carbon and fluorine (C–F) atom chains. [8] The strong C–F bond makes PFAS resistant to environmental and physiological breakdown processes and allows them to accumulate and persist in the environment and human tissues. [15] In the U.S., over 97% of the population has detectable concentrations of PFAS in their blood[16], and similar findings have been reported in studies from Spain,[17] Germany,[18] and China.[19] In addition to blood, PFAS have been detected in human lungs, brain, bone, liver, and kidneys.[15] PFAS have also been detected in the placenta, cord blood, and breast milk,[20–25] which further emphasizes the potential for early life exposures.

One consistent observation is an inverse association between PFAS concentrations and antibody responses to vaccinations in adults and children. [9,10,26–30] It is unclear which immune system components are affected by PFAS to generate a net effect of lower humoral responses. The production of antibodies results from the collaboration between multiple types of immune cells.[31] When the immune system is stimulated by vaccinations or infections, cells from the innate compartment, such as macrophages and neutrophils, trigger inflammatory processes that activate cells of the adaptive immune system (T and B-cells), which can then establish immune memory. Immune memory is the ability of cells to retain antigen-specific information from prior exposures to facilitate a faster and more targeted response upon subsequent encounters. Antibody production by B-cells is influenced by CD4+ T-cells, which consist of different specialized subpopulations tailored to the immune response needed for a specific pathogen or antigen.[32] These include Th1, Th2, Th17, T follicular helper cells (Tfh), and T regulatory cells (Treg).[33] Each CD4+ T-cell subset carries a unique set of functions that influence B-cells by modulating the strength, specificity, and durability of their produced antibodies. [34] For example, long-lived B-cells rely on Tfh cells for

durable antibody production because Tfh cells promote germinal center formation in lymph nodes via IL-21 secretion.[35–40] This interaction leads to B-cell proliferation, somatic hypermutation, and isotype class switching, ultimately resulting in high-affinity antibodies.[35,37] Other CD4+ T-cell subpopulations modulate antibody class switching by fine-tuning the context of the immune response required.[41–44] How early life exposures to PFAS affects these cell types is crucial for discovering how PFAS ultimately leads to changes in immune responses. This longitudinal study aims to identify alterations in CD4+ T-cells related to developmental PFAS exposure as a first step in understanding pathways implicated in PFAS-related immune dysfunction.

Methods:

Study design

Between December 2015 and April 2019, first-trimester pregnant women were recruited from outpatient clinics affiliated with the University of Rochester and enrolled in the Understanding Pregnancy Signals and Infant Development and Environmental Influences on Child Health Outcomes (UPSIDE-ECHO) study after informed consent. UPSIDE-ECHO is an ongoing prospective birth cohort designed to study prenatal exposures in relation to perinatal and child health outcomes in the Rochester, NY, area[45] that is part of the NIH ECHO program.[46] Eligibility criteria included maternal age 18 years or older, singleton pregnancy, no known substance abuse problems or history of psychotic illness, and the ability to communicate in English. Participants with major endocrine disorders (e.g., polycystic ovary syndrome) and high-risk pregnancies at baseline were not enrolled; additionally, infants born prior to 37 weeks of gestation or with congenital anomalies or significant health problems were excluded (n=9). Study visits, including physical exams, biospecimen collection, and questionnaire completion, were completed at each trimester and at birth, 6 and 12 months postnatally. This study protocol was approved by the University of Rochester School of Medicine and Dentistry Institutional Review Board (#58456).

Maternal and infant blood collection

During the second trimester of pregnancy (21 ± SD:1.8) gestational weeks), maternal serum from blood collected into EDTA tubes was frozen at -80°C until the time of analysis. For infant blood samples, cord blood was collected by venipuncture into sodium heparin tubes immediately after birth. Infant blood was collected into sodium heparin tubes at 6 and 12 months. Peripheral blood mononuclear cells (PBMC) were isolated using a Ficoll-Paque density gradient (GE Healthcare –

cytiva) and immediately cryopreserved in freezing media consisting of 10% heat-inactivated Fetal Bovine Serum (FBS)(Seradigm) and 10% DMSO (Amresco) at a cell concentration ranging from one to five million cells per mL.

PFAS analysis

Maternal serum isolated from the second trimester of pregnancy was sent to Wadsworth Center's Human Health Exposure Analysis Resource (HHEAR) Laboratory Hub for PFAS measurement. PFAS were measured using high-performance liquid chromatography (HPLC) and tandem mass spectrometry (MS/MS) detection and quantification, as described in Honda et al. (2018).[47] Fourteen PFAS were measured: NETFOSAA, NMFOSAA, PFBS, PFDA, PFDODA, PFHPA, PFHXA, PFHXS, PFNA, PFOA, PFOS, PFOSA, PFPEA, PFUNDA. The limit of detection (LOD) for individual PFAS varied from 0.02 to 0.03 ng/mL. To reduce exposure misclassification, four PFAS with 100% detection rate, namely PFOA, PFOS, PFNA, and PFHXS were included in the present analysis. Several quality control samples namely certificated standard reference materials (NIST SRM 1957 and SRM 1958), HHEAR QC pools, procedural blanks and matrix spikes were included in the analysis. The coefficient of variation in concentrations of four PFAS in SRMs, QC pools and matrix spikes between batches was <10%.

Infant T-cell phenotyping

Thawing, stimulation, and staining of PBMCs for mass cytometry were performed as detailed previously Scheible et al. (2012) and McDavid et al. (2022).[48,49] To control for batch effect and variability, all timepoints (birth, 6, and 12 months) from individual infant subjects were phenotyped in experimental batches that included 20 individual samples maximum. Each experimental batch also included one to two healthy adult PBMC controls that were carried across multiple batches. Cryopreserved sample vials were thawed at 37^{O}C in a water bath and washed twice with 10mL of RPMI 1640 (Corning) supplemented with L-glutamine, 10% heat-inactivated Fetal Bovine Serum (FBS) (R10), and 25U/uL Universal Nuclease (R10+n). Cord blood samples (CBMC) were treated with 3 mL 1x BD Pharm Lyse (BD Biosciences) supplemented with 25U/uL Universal Nuclease for 15 minutes to lyse red blood cells. Washed cells were rested overnight at 37^{O}C in a 5% CO_2 incubator. After overnight rest, samples were counted on a dual-fluorescence cell counter (Cellometer K2; Nexcelom/Revvity); samples less than 70% viable were excluded from the assay (5.9% of samples at birth, 14.6% at 6 months and 12.7% at 12 months). Cells were resuspended in R10 at a

concentration of 30 million-cells/mL, and 3 million cells were stimulated for 2 hours with 2ug/mL of *Staphylococcus aureus*, Enterotoxin Type B (SEB). GolgiPlug (BD Biosciences) and monensin (Sigma; 10 mM stock in EtOH) were added at 2 hours and further stimulated for 8 hours at 37^{O}C. Stimulated cells were washed with stain buffer (PBS + 2%FBS + 25U/uL Universal Nuclease) (SBn) and stained for 30 minutes at room temperature (RT) with unique combinations of metal-conjugated anti-human CD45 antibodies (Supplemental Table 1: Parameter Type, Barcodes) in a '6-choose-3' or '7-choose-3' live-cell barcoding scheme. [50–52] Barcoded samples were washed, resuspended in SBn, and then transferred into a single 15mL culture tube. The pooled sample was filtered, centrifuged, and stained for 30 minutes at RT with a cocktail of metal-conjugated anti-human antibodies for surface molecules (Supplemental Table 1: Parameter Type, Surface). Next, cells were washed with SBn then stained with Cell-ID Cisplatin-194Pt (Fluidigm/Standard BioTools) at 500nM/mL concentration for 5 minutes at RT. Cells were washed with SBn and fixed/permeabilized for 30 minutes at RT with Foxp3 Fixation-Permeabilization buffer (eBioscience) followed by a wash with Permeabilization Buffer (Perm-B) (eBioscience). Cells were intracellularly stained for 30 minutes at RT with Perm-B containing a cocktail of metal-conjugated anti-human antibodies (Supplemental Table 1: Parameter Type, Intracellular). Cells were washed, then fixed with 1 mL of 1.6% formaldehyde (Pierce) in PBS containing 500 nM of Cell-ID Intercalator-103Rh (Fluidigm/Standard BioTools) and incubated overnight at 4^{O}C. Fixed cells were washed with PBS, counted, and resuspended at a concentration of 13.75 million-cells/mL in filtered FBS with 10% DMSO (Amresco). Cells were aliquoted in Protein Lo-Bind tubes (Eppendorf) (2.75 million cells in 200ul) and stored at -80^{O}C. Following aliquoting and freezing, individual aliquots were prepared for acquisition on a CyTOF 2 or Helios mass cytometer (Fluidigm/Standard BioTools) by washing twice with 2 mL ultrapure water and resuspending in 3 mL ultrapure water containing 0.1x EQ Four Element Calibration Beads (Fluidigm/Standard BioTools). Aliquots were acquired using a Super Sampler (Victorian Airships).

Mass cytometry clustering pipeline

After the acquisition, source data was normalized using the Normalization Passport in CyTOF Software with default settings (Fluidigm, 7.0.5189). Normalized data was analyzed using a custom R-based workflow (github.com/nlaniewski/SOMnambulate). Briefly, unique live-cell barcoded pools were debarcoded to generate sample-specific *.fcs* files. FlowSOM[53] was used to generate clusters representing major PBMC immune cell populations (Supplemental Table 1: FlowSOM dimension,

PBMC). Based on per-cluster feature expression, annotations were defined. Selecting for only CD3+, CD4+, and CD8+ clusters representing T-cells, a second FlowSOM was generated using an expanded set of both surface and intracellular markers to define T-cell-specific sub-clustering results (Supplemental Table 1: FlowSOM dimension, T-cells). As with the PBMC clusters, per-cluster feature expressions were examined to define functional annotations. To aid in the interpretation of FlowSOM clusters, the nodes that comprise the self-organizing map (SOM) were visualized using Uniform Manifold Approximation and Projection (UMAP).[54] Default parameters were used to embed the nodes into two dimensions, using the same markers as those used to generate the respective SOM. Nodes (circles) were individually sized to represent the mean proportion of assigned cells and colored by their assigned cluster annotation. For each FlowSOM result (PBMC; T-cell), all cells were mapped on a per-sample basis, and the proportion of cells attributed to each cluster was calculated. The proportions used in subsequent visualizations and statistical models represent the percent of CD4+ T cells.

Measurement of covariates and selection of potential confounding variables.

After study enrollment in the first trimester, trained staff administered a questionnaire to obtain information on lifestyle, living environment, past pregnancies, medical conditions, medications used before, during, and after pregnancy, and sociodemographic information. Sociodemographic information, including self-reported maternal race and ethnicity, was collected at baseline, recognizing that these social constructs are associated with environmental exposures and maternal and child health outcomes.[55,56] Infant birth weight and sex at birth were obtained from electronic health records. Confounding variables were selected using a directed acyclic graph (DAG) informed by previous reports demonstrating an association with PFAS and T-cells (Supplemental Figure 1).[10,57] These were the categorical variables parity, infant sex, mode of delivery, maternal race, maternal education, and Medicaid during pregnancy, and the continuous variables maternal age, pre-pregnancy body mass index (BMI), annual income, and infant birth weight. The minimally sufficient set of variables from the DAG were categorical parity (0, 1, or 2+), infant sex at birth, and continuous pre-pregnancy BMI.

Statistical analysis

Descriptive characteristics for the entire sample are presented in Table 1. Specifically, frequencies and percentages for categorical variables, as well as means with standard deviations for

continuous variables are reported in this table. Wilcoxon rank-sum test was used for comparing mean differences between two groups for a continuous variable, Wilcoxon signed-rank test was used to assess mean differences between two time points. The association between two continuous variables was evaluated using Spearman's rank correlation test.

Owning to the longitudinal assessment of T-cell outcomes at multiple visits, two separate but related Linear Mixed-Effect regression (LMER) modeling strategies were employed to associate T-cell outcomes with individual PFAS concentrations, infant age, and their interactions. In both models, infant age is considered as a categorical variable with three levels (birth, 6 and 12 months), of which birth is considered as the baseline. In the first set of LMER models, a log-transformation designed to reduce the skewness is applied to the PFAS concentration levels: $x_{ij} = \log_2\left(\mathrm{Conc}_{ij} + 1\right)$, where Conc_{ij} represents the original PFAS concentration level for the *i*th subject at the *j*th visit. In the second set of LMER models, PFAS concentration levels were dichotomized as "above median" or "below median", permitting the estimation of differences in T-cell outcomes over time as discrete categories according to the categorical interactions between infant age and binary PFAS concentration levels. We call the second set of models as differences-over-time models.

For both approaches, a model is called a *crude model* if it only includes a PFAS level, infant age, and their interactions. It is called an *adjusted model*, if it also includes the following additional fixed effects: parity (0, 1, or 2+), infant sex, and pre-pregnancy BMI (continuous). A subject-specific random intercept was included in all models to account for serial correlation in the repeated T-cell measures. Unknown parameters in these models were estimated by the Restricted maximum likelihood (REML) criterion. Regression t-test implemented in R package *lmerTest*[58] was used to assess the statistical significance of a fixed effect of interest; *F*-tests as implemented in function linearHypothesis() in R package *car* [59] was used to test specific linear contrasts between infant ages. Results for the difference-over-time models were presented as differences in marginal mean percent with corresponding 95% confidence intervals, and pairwise comparisons were performed to contrast mean percentages between below and above median PFAS. Model assumptions, including normality, linearity, and homoscedasticity of the residuals, were visually evaluated by inspection of diagnostic plots. A p-value of less than 0.05 was considered statistically significant for individual hypothesis tests. For analyses involving multiple hypotheses, the Benjamini–

Hochberg procedure was employed to control the false discovery rate (FDR) at a level of 0.05. All statistical analyses were conducted using R Foundation for Statistical Computing version 4.3.3.[60]

Results:

Study Population

The analysis included 200 full-term infants (Supplemental Figure 2). Participants were selected from the larger UPSIDE-ECHO cohort if they had second-trimester maternal PFAS measured and infant T-cell phenotyping from at least one timepoint (birth, 6, or 12 months of age). Cohort characteristics are shown in Table 1. In summary, 71% of participants were between 26-35 years old at enrollment; 62.5% of the cohort self-identified as White, 20% as Asian, 8% as Black, 9% as Hispanic, and 10% as other. 52% reported having at least a bachelor's degree, and 43% were enrolled in Medicaid during pregnancy. Parity was categorized based on pregnancies preceding the current pregnancy (34.5% nulliparous, 39% primiparous, or 26.5% multiparous). The mean gestational age at birth was 39.74 ± SD:1.11 weeks, 76.5% of infants were born vaginally, and 52.5% were assigned male sex at birth. Among the 200 mother-infant pairs who contributed at least one observation to the current study, compared to birth, those with 6- or 12-month data tended to be older at the time of the child's birth, higher income and education, and more likely to report White race (Supplemental Table 2).

PFAS exposure

Table 2 shows the mean concentration and distribution of four PFAS (PFOS, PFOA, PFNA, and PFHXS) that were detected in 100% of the second-trimester maternal serum samples and, therefore, included in subsequent analysis. The concentrations and distribution of the ten additional PFAS measured are in Supplemental Table 3. PFOS was present at the highest mean concentration (2.87±2.13 ng/mL), followed by PFHXS (1.96±0.92 ng/mL), PFOA (0.68±0.51 ng/mL), and the lowest concentration being PFNA (0.33±0.36 ng/mL). Relative to the NHANES general population concentrations, PFOS, PFOA, and PFNA mean concentrations were lower. [61] PFOA and PFNA were the most strongly correlated (Rho=0.64, p-value= 0.0001), followed by PFOS and PFNA (Rho=0.58, p-value= 0.0002) and PFOS and PFOA (Rho = 0.53, p-value= 0.0005). PFHXS showed a moderate correlation with PFOS (Rho= 0.38, p-value= 0.021) and PFOA (Rho= 0.30, p-value =0.049); PFNA and PFHXS were the most weakly correlated (Rho= 0.23, p-value = 0.113).

Determinants of exposure for the UPSIDE-ECHO population can be found in Supplemental Table 4. Overall, the concentrations of all PFAS were lower, with higher maternal parity. Maternal PFAS concentrations in serum were lower when the fetal sex was female. Generally, mean PFAS concentrations were higher in white mothers and mothers with higher income and education, and mean PFAS concentrations were lower in older mothers and mothers with higher pre-pregnancy BMI. Participants with Medicaid during pregnancy had lower concentrations of PFAS.

Infant T-cell clustering and phenotyping

A 36-marker mass cytometry panel (Supplemental Table 1) was used to deeply immunophenotype infant immune cell populations over the first year of life. FlowSOM clustering algorithm was used to identify and group immune populations (Figure 1A). PBMC populations were identified as follows: γδ T-cells were identified as CD3+ TCRγδ+ cells, cytotoxic T-cells as CD3+ CD8+, helper T-cells as CD3+ CD4+, B-cells as CD19+, NK cells as CD56+, and monocytes as CD14+ cells. UMAP visualization of infant leukocytes revealed separation between the major immune populations, including T-cells, B-cells, NK cells, and monocytes (Figure 1B).

To test our specific hypothesis regarding the role of PFAS in T-cell development, we narrowed analyses to CD4+ T-cells. CD4+ T-cells from the first level of clustering (i.e., PBMC) were then selected for a second level of FlowSOM clustering using an expanded set of phenotypic and functional markers to identify unique CD4+ T-cell sub-clusters. This sub-clustering analysis identified 29 unique CD4+ T-cell sub-clusters (Supplemental Figure 3A-B). During the first year of life, naïve (CD45RA+) comprised most of the CD4+ T-cell compartment, while T-cells carrying markers of immunological memory (CD45RO+, CD45RA-) were a small fraction at birth and increased over time (Figure 1C-D). Within the memory (CD45RO+) compartment, canonical CD4+ T-cell subpopulations Th1 (IFNg+), Th2 (IL-4+), Th17 (IL-17A+), Tregs (FOXP3+ CD127-) and Tfh cells (IL-21+) were identified based on the expression of surface and intracellular markers that distinguish functional properties of these subpopulations (Figure 1E, Supplemental Figure 3B-C). The percentages of these CD4+ T-cell subpopulations increased over time (Figure 1F, Supplemental Table 5).

Maternal PFAS exposure associates with infant CD4+ T-cell frequencies in an age-dependent manner

Figure 2 shows the age-specific adjusted association for PFOS, PFOA, PFNA, and PFHXS and each CD4+ T-cell. The unadjusted and adjusted age-specific estimates for this model can be found in Supplemental Table 6. Overall, the associations between PFAS and CD4+ T-cells were stronger at 6- and 12-months of age versus birth; with statistical evidence of effect measure modification by age for Tfh, Th2, and Th1 cells, but not for Tregs or Th17 cells (Supplemental Table 7 and Supplemental Table 8). These associations were consistent for crude and adjusted models.

Tfh cells were inversely associated with maternal PFAS; each doubling of PFOS was associated with a 0.17 (95%CI of β: -0.30, -0.04) lower Tfh percentage measured at 12 months of age, a 0.05 (95%CI of β: -0.16, 0.06) lower Tfh percentage at 6 months, and a 0.08 (95%CI of β: -0.01, 0.16) greater Tfh percentage at birth (p-value for age interaction=0.002). Similar trends were observed between Tfh percentages and PFOA, PFNA and PFHXS (Figure 2A).

In contrast, Th2, Th1, and Treg cells were positively associated with maternal PFAS exposure. For Th2 cells, each doubling of PFOA was associated with a 0.30 (95%CI of β: 0.18, 0.41) greater Th2 percentage measured at 12 months of age, a 0.25 (95%CI of β: 0.12, 0.38) greater Th2 percentage at 6 months, and a 0.05 (95%CI of β: -0.04, 0.14) greater Th2 percentage at birth (p-value for age interaction = 0.000). Similar trends were observed between Th2 percentages and PFOS, PFNA, and PFHXS (Figure 2B). For Th1 cells, each doubling of PFNA was associated with a 0.11 (95%CI of β: 0.02, 0.20) greater Th1 percentage measured at 12 months of age and no association at 6 months of age or birth (p-value for age interaction = 0.054). Similar trends were observed between Th1 percentages and PFOS, PFOA, and PFHXS (Figure 2C).

For Tregs, each doubling of PFHXS was associated with a 0.11 (95%CI of β: 0.01, 0.22) greater Treg percentage measured at 12 months of age, a 0.06 (95%CI of β: -0.02, 0.15) greater Treg percentage at 6 months, and no association at birth (p-value for age interaction = 0.129). Similar trends were observed between Treg percentages and PFOS, PFOA, and PFNA (Figure 2D). No associations were observed between Th17 percentages and the doubling of PFOS, PFOA, PFNA, and PFHXS (Figure 2E).

Maternal PFAS exposure predicts CD4+ T-cell trajectories in infants.

Overall, independently of PFAS exposure group, the trajectory of each CD4+ T-cell subset showed increasing levels over time (Figure 3). Further, PFAS-dependent effects were more pronounced at later ages, especially 12 months of age. This was the case for Tfh, Th2, Th1, and Treg cells, but not

for Th17 cells. Unadjusted and adjusted age-specific marginal means and pairwise comparisons for below and above median PFAS can be found in Supplemental Tables 9 and 10, respectively. For Tfh cells and PFOS exposure, the adjusted negative association was strongest at 12 months of age, with a mean value for above median PFOS of 0.86 ± SD: 0.05 (95%CI:0.76, 0.96) versus a mean value for below median PFOS of 1.13 ± SD: 0.06 (95%CI:1.02, 1.24) (p-value for difference=0.002); similar trends were observed for PFOA and PFNA, and no differences were observed for PFHXS (Figure 3A). For Th2 cells and PFOA exposure, the adjusted positive association was present at 6 months but stronger at 12 months of age. At 12 months we observed a mean value for Th2 cells for above median PFOA of 0.44 ± SD: 0.03 (95%CI:0.37, 0.50) versus a mean value for below median PFOA of 0.32 ± SD: 0.04 (95%CI: 0.25, 0.39) (p-value for difference = 0.002); similar trends were observed for PFOS, PFNA, and PFHXS (Figure 3B). For Th1 cells and PFNA exposure, the adjusted positive association was observed at 12 months of age, with a mean value for above the median PFNA of 0.37 ± SD:0.02 (95%CI: 0.32, 0.41) versus a mean value for below median PFNA of 0.30 ± SD: 0.02 (95%CI: 0.25, 0.34) (p-value for difference = 0.019); similar trends were observed for PFOS, PFOA, and PFHXS (Figure 3C). For Treg cells and PFHXS exposure, the adjusted positive association was present at 6 months but stronger at 12 months of age; at 12 months we observed a Treg mean value for above the median PFHXS of 0.45 ± SD: 0.03 (95%CI: 0.40, 0.50) versus a mean value for below the median PFHXS of 0.32 ± SD: 0.03 (95%CI: 0.26, 0.38) (p-value for difference = 0.002); similar trends for 12 months but not 6 months were observed for PFOS, PFOA, and PFNA (Figure 3D). No differences between the mean value of Th17 cells for above versus below median PFOS, PFOA, PFNA, and PFHXS were observed (Figure 3E).

Discussion

In this prospective cohort study, we investigated the association between maternal PFAS exposure CD4+ T-cell subpopulations in infants over the first year of life. The potential of PFAS to affect the immune system has been widely reported in population studies across the world, with consistently observed reductions in antibody responses to common childhood vaccinations.[9,12] Yet, the specific immune cell components altered by PFAS exposure remain unknown. We found that increased concentrations of maternal PFAS were associated with a reduction in the percentage of Tfh cells, increased Th2, Th1, and Treg populations, and no differences in Th17 cells. Moreover, each association was stronger from birth to 12 months of age. These findings indicate that the potential effects of prenatal PFAS exposure may become more pronounced as the infant grows older. This

391 could be attributed to ongoing T-cell development in the first year of life, and that certain T-cell
392 subpopulations may not emerge until the infant is exposed to specific stimuli. As time passes and
393 T-cell subpopulations continue to develop, the impact of PFAS exposure on the cells becomes
394 more apparent.

395 The immune system protects against pathogens through a coordinated network of cells, tissues,
396 and organs. CD4+ T-cells orchestrate the immune response, making it specific to the type of stimuli
397 received and aiding in the generation and maintenance of immune memory. Particularly, Tfh cells
398 help direct B-cells to produce long-lasting, high-affinity antibodies essential for immune memory.[35]
399 This study revealed a negative association between the percentage of Tfh cells and maternal PFAS
400 exposure during pregnancy. A reduction in Tfh cells in infants is consistent with the observed
401 reductions in antibodies to childhood vaccinations.[27,28,62–66] This provides potential mechanistic
402 insights into this observation because Tfh cells are essential for mature and durable antibody
403 responses.[35,39,40,67]

404 Given the complexity of antibody responses, it is unlikely Tfh cells are the only immune cell type
405 altered by PFAS exposure. For example, we also observed that Tregs were enhanced with increased
406 maternal PFAS concentrations. Tregs are recognized for their immunosuppressive functions and
407 their capacity to inhibit the activation and proliferation of effector T-cells.[68,69] Studies have
408 demonstrated that Tregs can reduce immune responses to vaccinations by suppressing effector
409 responses.[70,71] An increase in Treg cells could suppress T-cell or B-cell responses, thereby
410 attenuating antibody production. More generally, an enrichment in Treg cells could support an
411 immunosuppressed environment, dampening the overall ability to fight infections. Therefore, an
412 increased proportion or function of Tregs could also contribute to reduced antibody titers that have
413 been observed in association with PFAS exposure.

414 In addition to Tfh and Tregs, our study found a positive association between the percent of Th1 and
415 Th2 cells with maternal PFAS concentrations. While Th1 and Th2 cells play important defense roles
416 during infections, excessive Th1 and Th2 activity can be involved in the immunopathogenesis of
417 several chronic health conditions, including allergy and autoimmunity.[72–77] Th1 cells are among the
418 predominant T-cell subpopulations in systemic autoimmune disorders, such as rheumatoid
419 arthritis[78], as well as organ-specific autoimmunity, such as Type 1 diabetes mellitus[79], and other
420 debilitating inflammatory disorders such as Crohn's disease.[80]

On the other hand, Th2 cells have been associated with the development of atopic and allergic diseases such as atopic dermatitis, eczema, chronic rhinosinusitis, and asthma.[77,81,82] While studies have associated PFAS exposure with allergic or autoimmune outcomes in children, the findings are inconsistent, with some showing no association.[83–94] Several studies examining the association between PFAS exposure and allergic outcomes in infants have measured IgE levels in umbilical cord serum. For instance, Okada et al. in 2012[87] reported lower umbilical cord IgE levels at birth associated with higher maternal PFOA, whereas Wang et al. in 2011[88] found increased IgE levels in cord blood associated with prenatal PFOA and PFOS. IgE plays an important role in the allergic response; however, baseline total IgE levels may not reliably predict allergic outcomes, particularly because they are not specific to a particular allergen. Additionally, a study by Oulhole et al. 2017 [95] found a positive association between PFAS concentrations and basophil counts in 5-year-old infants; while their study did not investigate allergic outcomes, it is well established that basophils play a crucial role in initiating Th2-mediated immunity.[96] Thus, an enhancement in Th2 responses operates in concert with these innate immune cells, which could lead to the development of adverse allergic outcomes. Type 2 cytokines such as IL-4, IL-5, and IL-13 have been associated with asthma development, and Th2 cells are the primary source of these cytokines.[75,81,82] Similar to allergic outcomes, evidence for the association between PFAS exposure and asthma has been mixed. Studies reporting negative associations between exposure to PFAS, and the risk of asthma were mainly conducted in children under the age of 10,[91,97] while those reporting a positive association were conducted in adolescents.[92,94,98] This emphasizes the importance of considering age and longitudinal analysis when studying immune-related outcomes in children.

Our findings reveal a 0.30 (95% CI: 0.18, 0.41) greater Th2 percentage associated with PFOA at 12 months. While the changes observed in the age-specific percentages of CD4+ T-cells in this study may appear small, these variation sizes have had health implications in previous studies. For instance, an estimated 1.5-2 fold increase in Th2 cells has been noted among infant patients with atopic dermatitis or bronchial asthma compared to healthy controls.[99,100] Using the mean Th2 percentage of 0.38% (± SD: 0.38) as a reference in our infants (Figure 1F, Supplemental Table 5), an increase of 0.30 indicates an overall 79% increase in Th2 cells. Further, numerous studies have shown that minor changes in the frequency of circulating T follicular helper (cTfh) cells correlate with antigen-specific antibody levels in humans[39,101–103], at ranges similar to the 18% reduction in Tfh cells we observed. Individuals with higher frequencies of cTfh cells typically exhibit more robust

453 antibody responses; this relationship has been observed in vaccine responses to hepatitis B[103],
454 yellow fever virus[102], and influenza[101], as well as among children infected with malaria[39].

455 Our findings provide strong evidence that maternal PFAS exposure affects the infant's immune
456 system. Differences in CD4+ T cell subpopulations as a function of maternal PFAS exposure
457 support the idea that PFAS are immunotoxic in human infants. As with all research studies using
458 human populations, this study has several strengths, as well as some limitations. One major
459 strength is that this is a longitudinal study with deep immunophenotyping, high-dimensional
460 analysis, and identification of infant CD4+ T-cell subpopulations. Additionally, since only healthy
461 pregnancies and full-term healthy infants were enrolled in the study, we partly removed the
462 potential for congenital-disease-related changes in CD4+ T-cell subpopulations that could
463 influence immunological outcomes. However, this study is not without limitations. The study
464 sample was relatively small (n=200) compared to larger cohort studies.[26,27] However, even these
465 larger cohort studies that showed negative associations between PFAS and antibody titers did not
466 include in-depth immunophenotyping. These previous studies, therefore, leave a gap in our
467 understanding of the cells responsible for coordinating the antibody response. Moreover, although
468 it is well established that PFAS can cross the placenta[20,104] and can be detected in the fetus[21], in the
469 current study, PFAS were only measured during the second trimester of pregnancy and not directly
470 in the infants. Although this is a limitation, this exposure window is a crucial period for potential T-
471 cell programming and development.[2,105] Human T-cell development begins around the 8th week of
472 pregnancy and continues after birth during infancy; exposures during T-cell development can
473 significantly affect the immune profile of the offspring. [106] For example, human cohort studies have
474 linked maternal exposure to pollutants and decreased T-cell-dependent immune defenses in
475 infants and children. [28,107,108] Further evidence that developmental exposures shape T-cell function
476 is provided by experimental studies, which provide strong evidence that in-utero exposure can
477 significantly and durably alter T-cell function later in life. [109]

478 Participants in the study had lower mean serum concentrations of PFOS, PFOA, and PFNA but
479 higher PFHXS compared to the general population levels reported by NHANES (2017-2018).[61] The
480 current study provides insights for ongoing risk assessment of PFAS exposures since the legacy
481 PFAS levels are declining over time[61] and our study suggests immunotoxic impacts in early life, even
482 at these lower levels.

Our results indicate stronger associations between maternal PFAS exposure and CD4+ T-cell subpopulations later during infancy compared to birth. This is likely due to the fact that T-cells are still developing at birth, and infants have not been exposed to the stimuli needed to activate and differentiate T-cell subpopulations. Ongoing PFAS exposure after birth is a key factor to consider. Recently, PFAS has been detected in human breast milk[22,23] and could represent a continuous source of maternally derived PFAS exposure in the early postnatal life. Rigorous studies to quantify the variation of PFAS in breast milk and formula or other postnatal exposures and immune development are warranted.

In conclusion, we report here an association between in utero exposure to PFAS and decreased percent of Tfh cells and increased percent of Th1, Th2, and Treg cells during the first year of life. These observations support that there are immunomodulatory effects of developmental PFAS exposure. These findings contribute to our understanding of potential mechanisms by which PFAS exposure lowers antibody titers in infants. Moreover, given that imbalances in T-cell subpopulations are associated with other diseases, in-depth profiling of infant T-cells suggests that in utero PFAS exposure may predispose to future immunopathogenesis.

514 **References**

515 1. Park JE, Botting RA, Domínguez Conde C, et al. A cell atlas of human thymic development
516 defines T cell repertoire formation. *Science*. 2020;367(6480):eaay3224.
517 doi:10.1126/science.aay3224

518 2. Zhang X, Zhivaki D, Lo-Man R. Unique aspects of the perinatal immune system. *Nat Rev*
519 *Immunol*. 2017;17(8):495-507. doi:10.1038/nri.2017.54

520 3. West LJ. Defining critical windows in the development of the human immune system. *Hum Exp*
521 *Toxicol*. 2002;21(9-10):499-505. doi:10.1191/0960327102ht288oa

522 4. Gómez-Roig MD, Pascal R, Cahuana MJ, et al. Environmental Exposure during Pregnancy:
523 Influence on Prenatal Development and Early Life: A Comprehensive Review. *Fetal Diagn Ther*.
524 2021;48(4):245-257. doi:10.1159/000514884

525 5. Prüss-Ustün A, Vickers C, Haefliger P, Bertollini R. Knowns and unknowns on burden of disease
526 due to chemicals: a systematic review. *Environ Health*. 2011;10(1):9. doi:10.1186/1476-069X-
527 10-9

528 6. Barouki R, Gluckman PD, Grandjean P, Hanson M, Heindel JJ. Developmental origins of non-
529 communicable disease: Implications for research and public health. *Environ Health*.
530 2012;11(1):42. doi:10.1186/1476-069X-11-42

531 7. Rychlik KA, Sillé FCM. Environmental exposures during pregnancy: Mechanistic effects on
532 immunity. *Birth Defects Research*. 2019;111(4):178-196. doi:10.1002/bdr2.1469

533 8. Buck RC, Franklin J, Berger U, et al. Perfluoroalkyl and polyfluoroalkyl substances in the
534 environment: Terminology, classification, and origins. *Integr Environ Assess Manag*.
535 2011;7(4):513-541. doi:10.1002/ieam.258

536 9. Antoniou E, Colnot T, Zeegers M, Dekant W. Immunomodulation and exposure to per- and
537 polyfluoroalkyl substances: an overview of the current evidence from animal and human
538 studies. *Arch Toxicol*. 2022;96(8):2261-2285. doi:10.1007/s00204-022-03303-4

10. Zhang X, Xue L, Deji Z, et al. Effects of exposure to per- and polyfluoroalkyl substances on vaccine antibodies: A systematic review and meta-analysis based on epidemiological studies. *Environmental Pollution*. 2022;306:119442. doi:10.1016/j.envpol.2022.119442

11. Blake BE, Fenton SE. Early life exposure to per- and polyfluoroalkyl substances (PFAS) and latent health outcomes: A review including the placenta as a target tissue and possible driver of peri- and postnatal effects. *Toxicology*. 2020;443:152565. doi:10.1016/j.tox.2020.152565

12. Zhang L, Louie A, Rigutto G, et al. A systematic evidence map of chronic inflammation and immunosuppression related to per- and polyfluoroalkyl substance (PFAS) exposure. *Environ Res*. 2023;220:115188. doi:10.1016/j.envres.2022.115188

13. Fenton SE, Ducatman A, Boobis A, et al. Per- and Polyfluoroalkyl Substance Toxicity and Human Health Review: Current State of Knowledge and Strategies for Informing Future Research. *Environ Toxicol Chem*. 2021;40(3):606-630. doi:10.1002/etc.4890

14. Birth Outcomes in Relation to Prenatal Exposure to Per- and Polyfluoroalkyl Substances and Stress in the Environmental Influences on Child Health Outcomes (ECHO) Program. doi:10.1289/EHP10723

15. Pérez F, Nadal M, Navarro-Ortega A, et al. Accumulation of perfluoroalkyl substances in human tissues. *Environment International*. 2013;59:354-362. doi:10.1016/j.envint.2013.06.004

16. Lewis RC, Johns LE, Meeker JD. Serum Biomarkers of Exposure to Perfluoroalkyl Substances in Relation to Serum Testosterone and Measures of Thyroid Function among Adults and Adolescents from NHANES 2011–2012. *International Journal of Environmental Research and Public Health*. 2015;12(6):6098. doi:10.3390/ijerph120606098

17. Cserbik D, Casas M, Flores C, et al. Concentrations of per- and polyfluoroalkyl substances (PFAS) in paired tap water and blood samples during pregnancy. *J Expo Sci Environ Epidemiol*. 2024;34(1):90-96. doi:10.1038/s41370-023-00581-7

18. Göckener B, Weber T, Rüdel H, Bücking M, Kolossa-Gehring M. Human biomonitoring of per- and polyfluoroalkyl substances in German blood plasma samples from 1982 to 2019. *Environment International*. 2020;145:106123. doi:10.1016/j.envint.2020.106123

19. Duan Y, Sun H, Yao Y, Meng Y, Li Y. Distribution of novel and legacy per-/polyfluoroalkyl substances in serum and its associations with two glycemic biomarkers among Chinese adult men and women with normal blood glucose levels. *Environment International*. 2020;134:105295. doi:10.1016/j.envint.2019.105295

20. Ma D, Lu Y, Liang Y, et al. A Critical Review on Transplacental Transfer of Per- and Polyfluoroalkyl Substances: Prenatal Exposure Levels, Characteristics, and Mechanisms. *Environ Sci Technol*. 2022;56(10):6014-6026. doi:10.1021/acs.est.1c01057

21. Mamsen LS, Björvang RD, Mucs D, et al. Concentrations of perfluoroalkyl substances (PFASs) in human embryonic and fetal organs from first, second, and third trimester pregnancies. *Environment International*. 2019;124:482-492. doi:10.1016/j.envint.2019.01.010

22. LaKind JS, Naiman J, Verner MA, Lévêque L, Fenton S. Per- and polyfluoroalkyl substances (PFAS) in breast milk and infant formula: A global issue. *Environmental Research*. 2023;219:115042. doi:10.1016/j.envres.2022.115042

23. Zheng G, Schreder E, Dempsey JC, et al. Per- and Polyfluoroalkyl Substances (PFAS) in Breast Milk: Concerning Trends for Current-Use PFAS. *Environ Sci Technol*. 2021;55(11):7510-7520. doi:10.1021/acs.est.0c06978

24. Pan Y, Zhu Y, Zheng T, et al. Novel Chlorinated Polyfluorinated Ether Sulfonates and Legacy Per-/Polyfluoroalkyl Substances: Placental Transfer and Relationship with Serum Albumin and Glomerular Filtration Rate. *Environ Sci Technol*. 2017;51(1):634-644. doi:10.1021/acs.est.6b04590

25. McAdam J, Bell EM. Determinants of maternal and neonatal PFAS concentrations: a review. *Environmental Health*. 2023;22(1):41. doi:10.1186/s12940-023-00992-x

26. Grandjean P, Andersen EW, Budtz-Jørgensen E, et al. Serum Vaccine Antibody Concentrations in Children Exposed to Perfluorinated Compounds. *JAMA*. 2012;307(4). doi:10.1001/jama.2011.2034

27. Grandjean P, Heilmann C, Weihe P, Nielsen F, Mogensen UB, Budtz-Jørgensen E. Serum Vaccine Antibody Concentrations in Adolescents Exposed to Perfluorinated Compounds. *Environ Health Perspect*. 2017;125(7):077018. doi:10.1289/EHP275

28. Granum B, Haug LS, Namork E, et al. Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood. *J Immunotoxicol*. 2013;10(4):373-379. doi:10.3109/1547691X.2012.755580

29. Kielsen K, Shamim Z, Ryder LP, et al. Antibody response to booster vaccination with tetanus and diphtheria in adults exposed to perfluorinated alkylates. *Journal of Immunotoxicology*. 2016;13(2):270-273. doi:10.3109/1547691X.2015.1067259

30. Kaur K, Lesseur C, Chen L, et al. Cross-sectional associations of maternal PFAS exposure on SARS-CoV-2 IgG antibody levels during pregnancy. *Environ Res*. 2023;219:115067. doi:10.1016/j.envres.2022.115067

31. Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. *Nat Rev Immunol*. 2015;15(3):160-171. doi:10.1038/nri3795

32. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. *Nat Rev Immunol*. 2014;14(1):24-35. doi:10.1038/nri3567

33. Zhu J, Paul WE. Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors: Transcription factor network in Th cells. *Immunological Reviews*. 2010;238(1):247-262. doi:10.1111/j.1600-065X.2010.00951.x

34. Parker DC. T cell-dependent B cell activation. *Annu Rev Immunol*. 1993;11:331-360. doi:10.1146/annurev.iy.11.040193.001555

35. Song W, Craft J. T follicular helper cell heterogeneity: Time, space, and function. *Immunol Rev*. 2019;288(1):85-96. doi:10.1111/imr.12740

36. Crotty S. T follicular helper cell differentiation, function, and roles in disease. *Immunity*. 2014;41(4):529-542. doi:10.1016/j.immuni.2014.10.004

37. Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and regulation of T follicular helper cells. *J Exp Med*. 2012;209(7):1241-1253. doi:10.1084/jem.20120994

38. Suh WK. Life of T Follicular Helper Cells. *Mol Cells*. 2015;38(3):195-201. doi:10.14348/molcells.2015.2331

39. Chan JA, Loughland JR, de la Parte L, et al. Age-dependent changes in circulating Tfh cells influence development of functional malaria antibodies in children. *Nat Commun*. 2022;13(1):4159. doi:10.1038/s41467-022-31880-6

40. Sage PT, Alvarez D, Godec J, von Andrian UH, Sharpe AH. Circulating T follicular regulatory and helper cells have memory-like properties. *J Clin Invest*. 2014;124(12):5191-5204. doi:10.1172/JCI76861

41. Luckheeram RV, Zhou R, Verma AD, Xia B. CD4+T Cells: Differentiation and Functions. *Clin Dev Immunol*. 2012;2012:925135. doi:10.1155/2012/925135

42. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Helper T Cells and Lymphocyte Activation. In: *Molecular Biology of the Cell. 4th Edition*. Garland Science; 2002. Accessed September 24, 2024. https://www.ncbi.nlm.nih.gov/books/NBK26827/

43. Stavnezer J, Guikema JEJ, Schrader CE. Mechanism and Regulation of Class Switch Recombination. *Annu Rev Immunol*. 2008;26:261-292. doi:10.1146/annurev.immunol.26.021607.090248

44. Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. *Nat Rev Immunol*. 2018;18(1):46-61. doi:10.1038/nri.2017.106

45. O'Connor T, Best M, Brunner J, et al. Cohort profile: Understanding Pregnancy Signals and Infant Development (UPSIDE): a pregnancy cohort study on prenatal exposure mechanisms for child health. *BMJ Open*. 2021;11(4):e044798. doi:10.1136/bmjopen-2020-044798

46. Knapp EA, Kress AM, Parker CB, et al. The Environmental Influences on Child Health Outcomes (ECHO)-Wide Cohort. *American Journal of Epidemiology*. 2023;192(8):1249. doi:10.1093/aje/kwad071

642 47. Honda M, Robinson M, Kannan K. A rapid method for the analysis of perfluorinated alkyl
643 substances in serum by hybrid solid-phase extraction. *Environ Chem*. 2018;15(2):92.
644 doi:10.1071/EN17192

645 48. Scheible K, Secor-Socha S, Wightman T, et al. Stability of T Cell Phenotype and Functional
646 Assays Following Heparinized Umbilical Cord Blood Collection. *Cytometry A*. 2012;81(11):937-
647 949. doi:10.1002/cyto.a.22203

648 49. McDavid A, Laniewski N, Grier A, et al. Aberrant newborn T cell and microbiota developmental
649 trajectories predict respiratory compromise during infancy. *iScience*. 2022;25(4):104007.
650 doi:10.1016/j.isci.2022.104007

651 50. Mei HE, Leipold MD, Maecker HT. Platinum-conjugated antibodies for application in mass
652 cytometry. *Cytometry Part A*. 2016;89(3):292-300. doi:10.1002/cyto.a.22778

653 51. Hartmann FJ, Simonds EF, Bendall SC. A Universal Live Cell Barcoding-Platform for Multiplexed
654 Human Single Cell Analysis. *Sci Rep*. 2018;8(1):10770. doi:10.1038/s41598-018-28791-2

655 52. Mei HE, Leipold MD, Schulz AR, Chester C, Maecker HT. Barcoding of live human peripheral
656 blood mononuclear cells for multiplexed mass cytometry. *J Immunol*. 2015;194(4):2022-2031.
657 doi:10.4049/jimmunol.1402661

658 53. Van Gassen S, Callebaut B, Van Helden MJ, et al. FlowSOM: Using self-organizing maps for
659 visualization and interpretation of cytometry data. *Cytometry Part A*. 2015;87(7):636-645.
660 doi:10.1002/cyto.a.22625

661 54. McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximation and Projection for
662 Dimension Reduction. Published online September 18, 2020. Accessed November 5, 2024.
663 http://arxiv.org/abs/1802.03426

664 55. Bulka CM, Bommarito PA, Fry RC. Predictors of toxic metal exposures among US women of
665 reproductive age. *J Expo Sci Environ Epidemiol*. 2019;29(5):597-612. doi:10.1038/s41370-019-
666 0152-3

667 56. Rivera-Núñez Z, Kinkade CW, Khoury L, et al. Prenatal perfluoroalkyl substances exposure and
668 maternal sex steroid hormones across pregnancy. *Environ Res*. 2023;220:115233.
669 doi:10.1016/j.envres.2023.115233

670 57. Liston A, Humblet-Baron S, Duffy D, Goris A. Human immune diversity: from evolution to
671 modernity. *Nat Immunol*. 2021;22(12):1479-1489. doi:10.1038/s41590-021-01058-1

672 58. Kuznetsova A, Brockhoff PB, Christensen RHB. **lmerTest** Package: Tests in Linear Mixed Effects
673 Models. *J Stat Soft*. 2017;82(13). doi:10.18637/jss.v082.i13

674 59. Fox J, Weisberg S, Price B, et al. car: Companion to Applied Regression. Published online
675 September 27, 2024. Accessed November 14, 2024. https://cran.r-
676 project.org/web/packages/car/index.html

677 60. Posit team. RStudio: Integrated Development Environment for R. Posit. 2024. Accessed
678 November 5, 2024. https://www.posit.co/

679 61. CDC. Final Report: Findings Across Ten Exposure Assessment Sites. Per- and Polyfluoroalkyl
680 Substances (PFAS) and Your Health. November 7, 2024. Accessed November 12, 2024.
681 https://www.atsdr.cdc.gov/pfas/final-report/index.html

682 62. Timmermann CAG, Jensen KJ, Nielsen F, et al. Serum Perfluoroalkyl Substances, Vaccine
683 Responses, and Morbidity in a Cohort of Guinea-Bissau Children. *Environmental Health*
684 *Perspectives*. 2020;128(8):087002. doi:10.1289/EHP6517

685 63. Abraham K, Mielke H, Fromme H, et al. Internal exposure to perfluoroalkyl substances (PFASs)
686 and biological markers in 101 healthy 1-year-old children: associations between levels of
687 perfluorooctanoic acid (PFOA) and vaccine response. *Arch Toxicol*. 2020;94(6):2131-2147.
688 doi:10.1007/s00204-020-02715-4

689 64. Timmermann CAG, Pedersen HS, Weihe P, et al. Concentrations of tetanus and diphtheria
690 antibodies in vaccinated Greenlandic children aged 7–12 years exposed to marine pollutants, a
691 cross sectional study. *Environmental Research*. 2022;203:111712.
692 doi:10.1016/j.envres.2021.111712

65. Mogensen UB, Grandjean P, Heilmann C, Nielsen F, Weihe P, Budtz-Jørgensen E. Structural equation modeling of immunotoxicity associated with exposure to perfluorinated alkylates. *Environmental Health*. 2015;14(1):47. doi:10.1186/s12940-015-0032-9

66. Stein CR, McGovern KJ, Pajak AM, Maglione PJ, Wolff MS. Perfluoroalkyl and polyfluoroalkyl substances and indicators of immune function in children aged 12–19 y: National Health and Nutrition Examination Survey. *Pediatr Res*. 2016;79(2):348-357. doi:10.1038/pr.2015.213

67. Sage PT, Sharpe AH. T Follicular Regulatory Cells in the Regulation of B cell Responses. *Trends Immunol*. 2015;36(7):410-418. doi:10.1016/j.it.2015.05.005

68. Wan YY. Regulatory T cells: immune suppression and beyond. *Cell Mol Immunol*. 2010;7(3):204-210. doi:10.1038/cmi.2010.20

69. Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. *Immunology*. 2008;124(1):13-22. doi:10.1111/j.1365-2567.2008.02813.x

70. Ndure J, Noho-Konteh F, Adetifa JU, et al. Negative Correlation between Circulating CD4+FOXP3+CD127− Regulatory T Cells and Subsequent Antibody Responses to Infant Measles Vaccine but Not Diphtheria–Tetanus–Pertussis Vaccine Implies a Regulatory Role. *Front Immunol*. 2017;8. doi:10.3389/fimmu.2017.00921

71. Stepkowski S, Bekbolsynov D, Oenick J, et al. The Major Role of T Regulatory Cells in the Efficiency of Vaccination in General and Immunocompromised Populations: A Review. *Vaccines (Basel)*. 2024;12(9):992. doi:10.3390/vaccines12090992

72. Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H. The role of the T cell in autoimmune inflammation. *Arthritis Research & Therapy*. 2005;7(2):S4. doi:10.1186/ar1703

73. Romagnani S. Th1/Th2 cells. *Inflamm Bowel Dis*. 1999;5(4):285-294. doi:10.1097/00054725-199911000-00009

74. Dardalhon V, Korn T, Kuchroo VK, Anderson AC. Role of Th1 and Th17 cells in organ-specific autoimmunity. *J Autoimmun*. 2008;31(3):252-256. doi:10.1016/j.jaut.2008.04.017

718 75. Deo SS, Mistry KJ, Kakade AM, Niphadkar PV. Role played by Th2 type cytokines in IgE mediated
719 allergy and asthma. *Lung India*. 2010;27(2):66-71. doi:10.4103/0970-2113.63609

720 76. Bosnjak B, Stelzmueller B, Erb KJ, Epstein MM. Treatment of allergic asthma: Modulation of Th2
721 cells and their responses. *Respiratory Research*. 2011;12(1):114. doi:10.1186/1465-9921-12-
722 114

723 77. Brandt EB, Sivaprasad U. Th2 Cytokines and Atopic Dermatitis. *J Clin Cell Immunol*.
724 2011;2(3):110. doi:10.4172/2155-9899.1000110

725 78. Luo P, Wang P, Xu J, et al. Immunomodulatory role of T helper cells in rheumatoid arthritis: a
726 comprehensive research review. *Bone & Joint Research*. 2022;11(7):426. doi:10.1302/2046-
727 3758.117.BJR-2021-0594.R1

728 79. Walker LSK, Herrath M von. CD4 T cell differentiation in type 1 diabetes. *Clinical and*
729 *Experimental Immunology*. 2015;183(1):16. doi:10.1111/cei.12672

730 80. Imam T, Park S, Kaplan MH, Olson MR. Effector T Helper Cell Subsets in Inflammatory Bowel
731 Diseases. *Front Immunol*. 2018;9. doi:10.3389/fimmu.2018.01212

732 81. Harker JA, Lloyd CM. T helper 2 cells in asthma. *The Journal of Experimental Medicine*.
733 2023;220(6):e20221094. doi:10.1084/jem.20221094

734 82. León B. Understanding the development of Th2 cell-driven allergic airway disease in early life.
735 *Front Allergy*. 2023;3:1080153. doi:10.3389/falgy.2022.1080153

736 83. Rappazzo K, Coffman E, Hines E. Exposure to Perfluorinated Alkyl Substances and Health
737 Outcomes in Children: A Systematic Review of the Epidemiologic Literature. *IJERPH*.
738 2017;14(7):691. doi:10.3390/ijerph14070691

739 84. von Holst H, Nayak P, Dembek Z, et al. Perfluoroalkyl substances exposure and immunity,
740 allergic response, infection, and asthma in children: review of epidemiologic studies. *Heliyon*.
741 2021;7(10):e08160. doi:10.1016/j.heliyon.2021.e08160

85. Smit L a. M, Lenters V, Høyer BB, et al. Prenatal exposure to environmental chemical contaminants and asthma and eczema in school-age children. *Allergy*. 2015;70(6):653-660. doi:10.1111/all.12605

86. Okada E, Sasaki S, Kashino I, et al. Prenatal exposure to perfluoroalkyl acids and allergic diseases in early childhood. *Environment International*. 2014;65:127-134. doi:10.1016/j.envint.2014.01.007

87. Okada E, Sasaki S, Saijo Y, et al. Prenatal exposure to perfluorinated chemicals and relationship with allergies and infectious diseases in infants. *Environmental Research*. 2012;112:118-125. doi:10.1016/j.envres.2011.10.003

88. Wang IJ, Hsieh WS, Chen CY, et al. The effect of prenatal perfluorinated chemicals exposures on pediatric atopy. *Environmental Research*. 2011;111(6):785-791. doi:10.1016/j.envres.2011.04.006

89. Goudarzi H, Miyashita C, Okada E, et al. Effects of prenatal exposure to perfluoroalkyl acids on prevalence ofallergic diseases among 4-year-old children. *Environment International*. 2016;94:124-132. doi:10.1016/j.envint.2016.05.020

90. Wen HJ, Wang SL, Chuang YC, Chen PC, Guo YL. Prenatal perfluorooctanoic acid exposure is associated with early onset atopic dermatitis in 5-year-old children. *Chemosphere*. 2019;231:25-31. doi:10.1016/j.chemosphere.2019.05.100

91. Jackson-Browne MS, Eliot M, Patti M, Spanier AJ, Braun JM. PFAS (per- and polyfluoroalkyl substances) and asthma in young children: NHANES 2013–2014. *International Journal of Hygiene and Environmental Health*. 2020;229:113565. doi:10.1016/j.ijheh.2020.113565

92. Humblet O, Diaz-Ramirez LG, Balmes JR, Pinney SM, Hiatt RA. Perfluoroalkyl Chemicals and Asthma among Children 12–19 Years of Age: NHANES (1999–2008). *Environmental Health Perspectives*. 2014;122(10):1129-1133. doi:10.1289/ehp.1306606

93. Zhu Y, Qin XD, Zeng XW, et al. Associations of serum perfluoroalkyl acid levels with T-helper cell-specific cytokines in children: By gender and asthma status. *Science of The Total Environment*. 2016;559:166-173. doi:10.1016/j.scitotenv.2016.03.187

769 94. Dong GH, Tung KY, Tsai CH, et al. Serum Polyfluoroalkyl Concentrations, Asthma Outcomes,
770 and Immunological Markers in a Case–Control Study of Taiwanese Children. *Environmental*
771 *Health Perspectives*. 2013;121(4):507-513. doi:10.1289/ehp.1205351

772 95. Oulhote Y, Shamim Z, Kielsen K, et al. Children's white blood cell counts in relation to
773 developmental exposures to methylmercury and persistent organic pollutants. *Reproductive*
774 *Toxicology*. 2017;68:207-214. doi:10.1016/j.reprotox.2016.08.001

775 96. Nakanishi K. Basophils are potent antigen-presenting cells that selectively induce Th2 cells.
776 *European Journal of Immunology*. 2010;40(7):1836-1842. doi:10.1002/eji.201040588

777 97. Beck IH, Timmermann CAG, Nielsen F, et al. Association between prenatal exposure to
778 perfluoroalkyl substances and asthma in 5-year-old children in the Odense Child Cohort.
779 *Environmental Health: A Global Access Science Source*. 2019;18(1). doi:10.1186/s12940-019-
780 0541-z

781 98. Kvalem HE, Nygaard UC, Lødrup Carlsen KC, Carlsen KH, Haug LS, Granum B. Perfluoroalkyl
782 substances, airways infections, allergy and asthma related health outcomes – implications of
783 gender, exposure period and study design. *Environment International*. 2020;134:105259.
784 doi:10.1016/j.envint.2019.105259

785 99. Kawamoto N, Kaneko H, Takemura M, et al. Age-related changes in intracellular cytokine
786 profiles and Th2 dominance in allergic children. *Pediatric Allergy and Immunology*.
787 2006;17(2):125-133. doi:10.1111/j.1399-3038.2005.00363.x

788 100. Brunner PM. Early immunologic changes during the onset of atopic dermatitis. *Annals of*
789 *Allergy, Asthma & Immunology*. 2019;123(2):152-157. doi:10.1016/j.anai.2019.03.033

790 101. Herati RS, Reuter MA, Dolfi DV, et al. Circulating CXCR5+PD-1+ Response Predicts Influenza
791 Vaccine Antibody Responses in Young Adults but not Elderly Adults. *The Journal of*
792 *Immunology*. 2014;193(7):3528-3537. doi:10.4049/jimmunol.1302503

793 102. Huber JE, Ahlfeld J, Scheck MK, et al. Dynamic changes in circulating T follicular helper cell
794 composition predict neutralising antibody responses after yellow fever vaccination. *Clinical &*
795 *Translational Immunology*. 2020;9(5):e1129. doi:10.1002/cti2.1129

103. Yin M, Xiong Y, Liang D, et al. Circulating Tfh cell and subsets distribution are associated with low-responsiveness to hepatitis B vaccination. *Molecular Medicine*. 2021;27(1):32. doi:10.1186/s10020-021-00290-7

104. Verner MA, Ngueta G, Jensen ET, et al. A Simple Pharmacokinetic Model of Prenatal and Postnatal Exposure to Perfluoroalkyl Substances (PFASs). *Environ Sci Technol*. 2016;50(2):978-986. doi:10.1021/acs.est.5b04399

105. Park JE, Jardine L, Gottgens B, Teichmann SA, Haniffa M. Prenatal development of human immunity. *Science*. 2020;368(6491):600-603. doi:10.1126/science.aaz9330

106. Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role in health and disease. *Nat Rev Immunol*. 2020;20(6):375-388. doi:10.1038/s41577-020-0285-6

107. Hochstenbach K, van Leeuwen DM, Gmuender H, et al. Toxicogenomic profiles in relation to maternal immunotoxic exposure and immune functionality in newborns. *Toxicol Sci*. 2012;129(2):315-324. doi:10.1093/toxsci/kfs214

108. Stølevik SB, Nygaard UC, Namork E, et al. Prenatal exposure to polychlorinated biphenyls and dioxins from the maternal diet may be associated with immunosuppressive effects that persist into early childhood. *Food and Chemical Toxicology*. 2013;51:165-172. doi:10.1016/j.fct.2012.09.027

109. Boule LA, Winans B, Lawrence BP. Effects of developmental activation of the AhR on CD4+ T-cell responses to influenza virus infection in adult mice. *Environ Health Perspect*. 2014;122(11):1201-1208. doi:10.1289/ehp.1408110

824 **Table 1**: Infant and maternal characteristics. (n=200)

Characteristic	**Mean ± SD**
Gestational Age (weeks)	39.74 ± 1.11
Birth Weight (grams)	3411.39 ± 464.49
Maternal Age	**N (%)**
18-25	41(20.5)
26-35	142(71)
36+	17(8.5)
Pre-pregnancy BMI	
Underweight	1(0.5)
Normal Weight	90(45)
Overweight	50(25)
Obese	59(29.5)
Annual Income	
Lower Class	41(20.5)
Lower-Middle Class	48(24)
Middle Class	40(20)
Upper-Middle Class	34(17)
Upper Class	19(9.5)
Not Reported	18(9)
Parity	
0	69(34.5)
1	78(39)
2+	53(26.5)
Infant Sex	
Male	105(52.5)
Female	95(47.5)
Mode of Delivery	
Vaginal	153(76.5)
Caesarian	47(23.5)
Maternal Race	
White	125(62.5)
Asian	40(20)
Black	16(8)
Hispanic	9(4.5)
Other	10(5)
Maternal Education	
HS or Less	64(32)
Some college	31(15.5)
Bachelors	54(27)

Postgraduate	50(25)
Not Reported	1(0.5)
Medicaid During Pregnancy	
No	114(57)
Yes	86(43)

BMI: Body Mass Index, SD: Standard deviation, HS: High School

853 **Table 2:** Distribution of perfluoroalkyl substances (PFAS) in maternal plasma (ng/mL).

PFAS	**Mean**	**SD**	**Min**	**1st Q**	**Median**	**3rd Q**	**Max**
PFOS	2.87	2.13	0.61	1.83	2.51	3.22	21.30
PFOA	0.68	0.51	0.06	0.40	0.59	0.83	5.45
PFNA	0.33	0.36	0.06	0.17	0.24	0.35	2.87
PFHXS	1.96	0.92	0.56	1.38	1.75	2.42	7.17

854 PFOS: perfluorooctanesulfonic acid, PFOA: perfluorooctanoic acid, PFHxS: perfluorohexane
855 sulfonic acid, PFNA: perfluorononanoic acid, PFDA: perfluorodecanoic acid, SD: Standard
856 Deviation, Min: minimum, Max: Maximum, LOD: limit of detection, Q: quantile.

857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873

Main Text Figure Captions

Figure 1: *Identification of CD4+ T-cell subpopulations in infants and their age-associated frequencies*.

(A) Study design and T-cell analysis pipeline. (B) Uniform Manifold Approximation and Projection (UMAP) representation of FlowSOM nodes colored by major peripheral blood mononuclear cells (PBMC): CD4+, CD8+, CD14+, CD19+, CD56+, TCRγδ; (C) Stacked bar graph denoting the proportion of CD45RA+ and CD45RO+ CD4+ T-cell subpopulations at birth, 6 and 12 months of age. (D-E) UMAP representation of FlowSOM nodes colored by expression of (D) CD45 isoform type (CD45RA+ or CD45RO+) within CD4+ T-cell FlowSOM nodes, and (E) CD4+ T-cell sub-cluster annotations based on the following marker expression: Treg (FOXP3+CD127-), Th1(IFNγ+), Th17 (IL-17A+), Tfh (IL-21+), Th2 (IL-4+), Naïve-cytokine-negative (TN). Circle size on UMAPs represents the relative mean count of total cells assigned to each FlowSOM node. (F) Frequency of CD4+ T-cells in cord blood at birth and PBMC at six and twelve months. Each dot on the boxplots denotes data from an individual infant at the indicated age; scales for boxplots are fixed.

Figure 2: *Maternal PFAS exposure associates with infant CD4+ T-cell frequencies in an age-dependent manner*.

The plots illustrate the regression lines for the age-specific average marginal effects of the association between continuous maternal PFAS (ng/mL) exposure and infant CD4+ T-cell percentage. Rows represent individual CD4+ T-cells: (A) T follicular helper cells, (B) T helper 2 cells, (C) T helper 1 cells, (D) T regulatory cells, and (E) T helper 17 cells. Columns represent individual PFAS; PFOS, PFOA, PFNA, and PFHXS were $\log_2$ transformed. The colors represent the infant age: birth (grey), 6 months (orange), and 12 months (blue). Each dot represents an individual infant at the indicated age. Age-specific average marginal effects (β) were adjusted for the categorical covariates parity, infant sex, and continuous pre-pregnancy body mass index. Parenthesis next to each age-specific β contains the 95% confidence interval for the estimate. Pairwise comparisons between the age-specific βs are represented by the brackets. Asterisks denote statistically significant (p-value < 0.05), and 'ns' indicates non-statistically significant differences between age-specific βs. Axis are independent for each CD4+ T-cell subpopulation and each PFAS. Supplemental Tables 6, 7, and 8 contain corresponding numeric data.

Figure 3: *Maternal PFAS exposure predicts CD4+ T-cell trajectories in infants*.

The plots illustrate differences-over-time between infant CD4+ T-cell subpopulations by a categorical PFAS value (below versus above median value). Rows represent individual CD4+ T-cells: (A) T follicular helper cells, (B) T helper 2 cells, (C) T helper 1 cells, (D) T regulatory cells, and (E) T helper 17 cells. Columns represent individual PFAS (PFOS, PFOA, PFNA, and PFHXS). The colors represent the categorical PFAS value: below the median (pink) and above the median (blue). Dots denote the predicted marginal mean of each CD4+ T-cell subpopulation at the indicated age. Marginal means were adjusted for the categorical covariates parity, infant sex, and continuous pre-pregnancy body mass index. Error bars represent the standard error of the marginal means. P-values denote the statistical significance between marginal means contrasting below vs. above the median PFAS; the contrast was considered statistically significant if the p-value < 0.05. The y-axis is independent for each CD4+ T-cell subpopulation. Supplemental Tables 9, 10, and 11 contain corresponding numeric data.

Acknowledgments:

Authors would like to acknowledge the support of the mothers and infants participating in UPSIDE-ECHO, UPSIDE-ECHO staff, University of Rochester Flow Cytometry Core, Scheible lab members Adam Geber, Janiret Narvaez Miranda, Dean for their technical assistance. Research reported in this publication was supported by the funding sources: NIH (OD) UH3OD023349, NIH (OD) UG3OD02349, NIH (NIAID) T32AI007285, NIH (NIEHS) P30ES001247, NIH (NIEHS) R01ES036197, NIH (NICHD) R01HD083369, NIH (NCATS) University of Rochester Clinical and Translational Science Award UL1TR002001. The Wynne Center for Family Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.